Regarding the cell lines expressing lower PD-L1 levels, BT-549 was killed by ADCC only at a higher NK:BC ratio of 10:1, while Avelumab did not increase MDA-MB-468 cell lysis in either of the two conditions (Figure 1C). This evidence concerns the gene CD274 and breast cancer.